VIDAS offers a flexible and easy way to rapidly detect IgM & IgG antibodies of individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
- Detects the presence of antibodies by using the S1/receptor-binding domain (RBD) of the SARS- CoV-2 S protein
- Reliable results in 27 minutes
- Two tests with the same protocol to differentiate lgM & lgG results
- Provides index value and no equivocal zone
- Ideal for either individual or batch testing
- Ready-to-use reagents with calibration materials included in kits
- Available on all VIDAS platforms (MINI VIDAS, VIDAS, VIDAS 3)
- Minimal maintenance and easy to use
VIDAS® SARS-COV-2 IgM & IgG is manufactured and approved for use by the Therapeutic Goods Administration (TGA) .
Buy VIDAS® SARS-COV-2 IgM & IgG for Detecting SARS-CoV-2 for Your WorkPlace
If your company or organisation is interested in rapid testing solutions, contact us today for help procuring VIDAS® SARS-COV-2 IgM & IgG for Detecting SARS-CoV-2 for detecting SARS-CoV-2 or other rapid tests authorised by the Therapeutic Goods Administration (TGA) .
If you’re interested in rapid testing solutions, contact us today for a quote. You can also place an order for VIDAS® SARS-COV-2 IgM & IgG for Detecting SARS-CoV-2 or other rapid tests approved by the TGA.
Our team at Rapid Tests Australia can also assist with implementing a rapid testing program to protect your workplace from the risks of COVID-19.